GB2612467B - Genetic modification of mammalian cells to confer resistance to CSF1R antagonists - Google Patents

Genetic modification of mammalian cells to confer resistance to CSF1R antagonists

Info

Publication number
GB2612467B
GB2612467B GB2219686.9A GB202219686A GB2612467B GB 2612467 B GB2612467 B GB 2612467B GB 202219686 A GB202219686 A GB 202219686A GB 2612467 B GB2612467 B GB 2612467B
Authority
GB
United Kingdom
Prior art keywords
csf1r
antagonists
mammalian cells
genetic modification
confer resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2219686.9A
Other languages
English (en)
Other versions
GB202219686D0 (en
GB2612467A (en
Inventor
Davtyan Hayk
Hasselmann Jonathan
Blurton-Jones Mathew
Paul Chadarevian Jean
Spitale Robert
Gandhi Sunil
England Whitney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of GB202219686D0 publication Critical patent/GB202219686D0/en
Publication of GB2612467A publication Critical patent/GB2612467A/en
Application granted granted Critical
Publication of GB2612467B publication Critical patent/GB2612467B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
GB2219686.9A 2021-04-01 2022-04-01 Genetic modification of mammalian cells to confer resistance to CSF1R antagonists Active GB2612467B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163169578P 2021-04-01 2021-04-01
US202163236951P 2021-08-25 2021-08-25
PCT/US2022/023139 WO2022212897A1 (en) 2021-04-01 2022-04-01 Genetic modification of mammalian cells to confer resistance to csf1r antagonists

Publications (3)

Publication Number Publication Date
GB202219686D0 GB202219686D0 (en) 2023-02-08
GB2612467A GB2612467A (en) 2023-05-03
GB2612467B true GB2612467B (en) 2025-11-19

Family

ID=83456857

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2219686.9A Active GB2612467B (en) 2021-04-01 2022-04-01 Genetic modification of mammalian cells to confer resistance to CSF1R antagonists

Country Status (8)

Country Link
US (3) US12421517B2 (https=)
EP (1) EP4314003A4 (https=)
JP (1) JP2024513003A (https=)
AU (1) AU2022252407A1 (https=)
CA (1) CA3215311A1 (https=)
DE (4) DE112022000079T5 (https=)
GB (1) GB2612467B (https=)
WO (1) WO2022212897A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12612599B2 (en) 2018-09-10 2026-04-28 Savanna Biotherapeutics, Inc. Compositions and methods for microglia replacement therapy
CA3215311A1 (en) 2021-04-01 2022-10-06 The Regents Of The University Of California Genetic modification of mammalian cells to confer resistance to csf1r antagonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL377714A1 (pl) * 2002-11-26 2006-02-06 Cold Spring Harbor Laboratory Białka oddziałujące z receptorową tyrozynową fosfatazą białkową DEP-1 oraz sposoby ich wykorzystania
US9044503B2 (en) 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
WO2006069203A2 (en) 2004-12-22 2006-06-29 California Institute Of Technology Methods for proteomic profiling using non-natural amino acids
WO2009089635A1 (en) 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
US20120183509A1 (en) 2009-04-28 2012-07-19 Harald Neumann Microglial precursor cells for the treatment of malignant neoplasms of the central nervous system
WO2010144678A2 (en) 2009-06-10 2010-12-16 The General Hospital Corporation Generation of vascularized human heart tissue and uses thereof
JP6312436B2 (ja) 2010-11-16 2018-04-18 ニューロダイン ライフ サイエンシズ インコーポレイテッドＮｅｕｒｏｄｙｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ネプリライシンの発現および活性を増大させるための方法および医薬組成物
DK2694644T3 (en) 2011-03-30 2018-04-16 Cellular Dynamics Int Inc Priming of pluripotent stem cells for neural differentiation
EP3092305B1 (en) 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
WO2016109813A2 (en) 2014-12-31 2016-07-07 Wisconsin Alumni Research Foundation Human pluripotent stem cell-based models for predictive developmental neural toxicity
US10081792B2 (en) 2014-12-31 2018-09-25 Wisconsin Alumni Research Foundation Derivation of human microglia from pluripotent stem cells
JP6774952B2 (ja) 2015-01-16 2020-10-28 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 多能性幹細胞のマクロファージへの分化
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2016210313A1 (en) 2015-06-24 2016-12-29 Whitehead Institute For Biomedical Research Culture medium for generating microglia from pluripotent stem cells and related methods
JP7235507B2 (ja) 2016-03-03 2023-03-08 ニューヨーク ステム セル ファウンデーション インコーポレイテッド 多能性幹細胞由来のミクログリアならびにその作製および使用方法
US20170369904A1 (en) 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
JP6963555B2 (ja) 2016-09-02 2021-11-10 タカラバイオ株式会社 多能性幹細胞からミクログリアを得る方法
JP7248571B2 (ja) 2016-10-05 2023-03-29 フジフィルム セルラー ダイナミクス，インコーポレイテッド ＭｅＣＰ２が破壊された誘導多能性幹細胞からの成熟系列の生成
US11957713B2 (en) 2016-10-14 2024-04-16 Children's Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
EP4272551A3 (en) 2017-02-28 2024-03-06 The Regents of the University of California Differentiation and use of human microglia-like cells from pluripotent stem cells and hematopoietic progenitors
WO2019118951A2 (en) 2017-12-15 2019-06-20 Duke University Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system
WO2019246273A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
EP3833762A4 (en) * 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
US12612599B2 (en) * 2018-09-10 2026-04-28 Savanna Biotherapeutics, Inc. Compositions and methods for microglia replacement therapy
WO2020069515A1 (en) 2018-09-28 2020-04-02 Memorial Sloan-Kettering Cancer Center Stem cell-derived human microglial cells, methods of making and methods of use
US12419915B2 (en) 2019-03-13 2025-09-23 The Broad Institute, Inc. Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
WO2020232512A1 (en) 2019-05-22 2020-11-26 The Council Of The Queensland Institute Of Medical Research Microglial cells and methods of use thereof
AU2020293287A1 (en) 2019-06-14 2022-01-06 FUJIFILM Cellular Dynamics, Inc. Methods for the production of multiple lineages from induced pluripotent stem cells using charged surfaces
WO2021026294A1 (en) 2019-08-06 2021-02-11 Children's Medical Center Corporation Methods and compositions for reconstituting microglia
US11866734B2 (en) 2019-08-26 2024-01-09 Taipei Veterans General Hospital Super enhancer for driving pluripotency network and stemness circuitry
WO2021221879A1 (en) 2020-05-01 2021-11-04 Albert Einstein College Of Medicine Compositions and methods for using transplanted microglia as a vehicle for widespread delivery of cells and other biologic agents to the brain
WO2021247710A2 (en) 2020-06-02 2021-12-09 The Regents Of The University Of California Stem-cell based biomarker discovery
GB202011871D0 (en) 2020-07-30 2020-09-16 Cambridge Entpr Ltd Composition and method
WO2022040798A1 (en) 2020-08-25 2022-03-03 University Health Network Compositions and methods for generating human yolk sac-like hematopoietic cells
CA3215311A1 (en) 2021-04-01 2022-10-06 The Regents Of The University Of California Genetic modification of mammalian cells to confer resistance to csf1r antagonists

Also Published As

Publication number Publication date
US20250002920A1 (en) 2025-01-02
DE202022003132U1 (de) 2025-02-17
DE202022003066U1 (de) 2024-09-19
US12421517B2 (en) 2025-09-23
US20230203500A1 (en) 2023-06-29
CA3215311A1 (en) 2022-10-06
GB202219686D0 (en) 2023-02-08
US20230248775A1 (en) 2023-08-10
AU2022252407A9 (en) 2023-10-26
JP2024513003A (ja) 2024-03-21
EP4314003A4 (en) 2025-03-12
DE112022000079T5 (de) 2023-06-15
EP4314003A1 (en) 2024-02-07
AU2022252407A1 (en) 2023-10-12
WO2022212897A1 (en) 2022-10-06
DE202022002866U1 (de) 2024-03-20
GB2612467A (en) 2023-05-03

Similar Documents

Publication Publication Date Title
GB2612467B (en) Genetic modification of mammalian cells to confer resistance to CSF1R antagonists
EP2398937A4 (en) ELECTROLYTIC CELL AND METHOD FOR THEIR USE
EP2782996A4 (en) POPULATIONS OF HEMATOPOETIC PROCEDURES AND METHOD FOR ENRICHING STEM CELLS THEREFOR
EP2547764A4 (en) METHOD FOR LEARNING THE DIFFERENTIATION OF PLURIPOTENTER STEM CELLS IN MESODERMAL CELLS
EP2893001A4 (en) METHOD FOR CULTIVATING MESENCHYMAL STEM CELLS
IL224775A (en) Cell non-static aggregate culture
PL2611907T3 (pl) Różnicowanie pluripotencjalnych komórek macierzystych
EP2545928A4 (en) CELL PREPARATION WITH MESENCHYMAL STEM CELLS AND METHOD OF MANUFACTURING THEREOF
IL234095B (en) Growth of mesenchymal stem cells in culture
EP2414548A4 (en) GENE EXPRESSION ANALYSIS IN SINGLE CELLS
EP2542666A4 (en) CULTURE ADDITIVES FOR PROMOTING A STEM CELL PROGRAMMING AND DIFFERENTIATION REACTION
EP2440652A4 (en) METHOD FOR CULTIVATING STEM CELLS AND PRECURSOR CELLS
IL226666B (en) Methods of generating corneal cells and cell populations comprising same
EP2453921A4 (en) DIFFERENTIATION OF MESENCHYMAL STEM CELLS
HUE11738351T2 (hu) Eljárás rekombináns ADAMTS13 elõállítására sejttenyészetben
EP2611909A4 (en) DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
EP2456853A4 (en) USE OF STEM CELLS FOR REDUCED LEUKOCYTE EXTRACATION
MX2011011316A (es) Electrodo para evolucion de oxigeno en proceso electroliticos industriales.
EP2726620A4 (en) CONSTITUTATIVE ACTIVE ABA RECEPTOR MUTANTS
EP2531853A4 (en) USING NEW MARKERS FOR PLURIPOTENTIAL STEM CELLS
EP2603583A4 (en) METHOD FOR INDUCING THE DIFFERENTIATION OF PLURIPOTENTIAL STEM CELLS IN GERM CELLS
HK40108804A (en) Genetic modification of mammalian cells to confer resistance to csf1r antagonists
IN2015DN01407A (https=)
IT1395109B1 (it) Bioreattore per la stimolazione di cellule staminali
EP2876160A4 (en) DIFFERENTIAL MARKER AND DIFFERENTIATION CONTROL FOR EYE CELLS

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20230511 AND 20230517